With the cost of developing drugs continually rising, squeezing every last penny out of existing drugs has become a key strategy for the pharmaceuticals industry. Life-cycle extension, in which companies try to extend their drugs' period of market exclusivity, has been the most popular strategy to date. However, changes in legislation and, more importantly, increasingly sophisticated generics manufacturers have trained R&D companies to use a broad set of patent life extension techniques a routine procedure in their product life cycle management plans. Manufacturers now have to try even harder to get value for their R&D spend.
|
Categories
All
Archives |